問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare (在職)

Division of Nephrology

Division of General Internal Medicine

Taipei WanFang Hospital (Managed by Taipei Medical Univeristy)

Division of Nephrology

更新時間：2023-09-19

許永和HSU, YUNG-HO
  • Principal Investigator
  • Clinical Trial Experience (year) -18 years -4 個月

Recruiting Trial

33Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

許永和

List

48Cases

2026-05-31 - 2030-06-30

Phase III

Not yet recruiting
A Phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group trial evaluating the efficacy, safety, and tolerability of cenerimod in combination with background therapy in adult patients with systemic lupus erythematosus and active lupus nephritis.

  • Condition/Disease

    Nephritis and nephropathy not specified as acute or chronic, classified elsewhere | Systemic lupus erythematosus

  • Test Drug

    Cenerimod

Participate Sites
9Sites

Not yet recruiting9Sites

2021-03-01 - 2026-12-31

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
5Sites

Not yet recruiting3Sites

Recruiting2Sites

2026-06-01 - 2028-12-31

Phase III

Not yet recruiting
A randomized, double-blind, parallel-group, phase 3 trial was conducted to evaluate the efficacy, safety, and tolerability of elecoglipron compared to placebo in adult patients with type 2 diabetes, impaired renal function, and receiving background treatment with dapagliflozin (Eluminate-4).

  • Condition/Disease

    Type 2 diabetes

  • Test Drug

    Dapagliflozin Elecoglipron

Participate Sites
12Sites

Not yet recruiting1Sites

2021-12-31 - 2030-12-31

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
8Sites

Recruiting8Sites

2022-03-31 - 2024-08-30

Phase II

Completed
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
8Sites

Not yet recruiting8Sites

2026-08-31 - 2029-05-11

Phase II

Not yet recruiting
A phase 2, multicenter, open-label trial evaluating the safety and efficacy of JADE101 in participants with immunoglobulin-induced nephropathy (JUNIPER).

  • Condition/Disease

    Immunoglobulin A nephropathy

  • Test Drug

    JADE101 Solution for Injection

Participate Sites
6Sites

Not yet recruiting6Sites

2026-10-01 - 2030-03-31

Phase II/III

Not yet recruiting
A sequential phase 2/3 trial, initially a single-arm, open-label trial in adults, followed by a randomized, placebo-controlled, double-blind, multicenter trial in adults and adolescents, will evaluate the efficacy and safety of Pegcetacoplan in treating focal segmental glomerulosclerosis.

  • Condition/Disease

    Focal segmental glomerulosclerosis

  • Test Drug

    Pegcetacoplan (APL-2) 1080 mg in 20 mL (54 mg/mL) or Placebo solution Pegcetacoplan (APL-2) 1080 mg in 20mL (54mg/ml) solution

Participate Sites
5Sites

Not yet recruiting5Sites

2024-03-15 - 2031-12-31

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
10Sites

Not yet recruiting1Sites

Recruiting9Sites

2024-09-30 - 2027-12-31

Phase II

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
6Sites

Not yet recruiting5Sites

Recruiting1Sites

2024-09-30 - 2028-11-30

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
8Sites

Recruiting8Sites

1 2 3 4 5
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB